To overcome this limitation, pre-clinical studies have demonstrated that joint pharmacological inhibition with rezatapopt and venetoclax can successfully compensate for this deficiency to induce apoptosis in TP53-Y220C mutant AML and MDS [179]. The gene discussed is TP53; the disease is myelodysplastic syndrome.